1532P Nab-paclitaxel plus S1 with or without sintilimab in metastatic pancreatic ductal adenocarcinoma: A single-center, retrospective study

Abstract

Including RDI in the model did not improve the ability to predict disease control: AUC¼0.79 (95%CI, 0.73 e 0.85) with RDI vs AUC¼0.78 (95%CI, 0.72 e 0.85) without. Similar results were observed for RR.Conclusions: RDI of each FOLFIRINOX's component and cRDI were neither associated with DCR, nor with RR. Pharmacological data would help interpret this finding.Legal entity responsible for the study: GERCOR.